Vaccines
TABLE OF CONTENTS
Volume 82, Issue 6 (December 2007)
Editorial |
News and Views |
Perspectives |
State of the Art |
Research |
Discovery & Development |
Regulation & Use
In This Issue
In This Issue
Clin Pharmacol Ther 82: 621; doi:10.1038/sj.clpt.6100445
See also: Point/Counterpoint by CampbellSee also: State of the Art by Ovsyannikova et al. See also: Article by Hoelscher et al. See also: Article by RobinsonSee also: Ethics by Schwartz et al. See also: Point/Counterpoint by OsterholmEditorial
Pharmacology, Vaccinomics, and the Second Golden Age of Vaccinology
G A Poland
Clin Pharmacol Ther 82: 623-626; doi:10.1038/sj.clpt.6100379
News and Views
Highlights
News and Views
Clin Pharmacol Ther 82: 628-629; doi:10.1038/sj.clpt.6100440
ASCPT News
News and Views
Clin Pharmacol Ther 82: 630-631; doi:10.1038/sj.clpt.6100439
Perspectives
Point/Counterpoint
Pandemic Flu Vaccine: Are We Doing Enough?
J D Campbell
Clin Pharmacol Ther 82: 633-635; doi:10.1038/sj.clpt.6100417
Pandemic Influenza Vaccine: The US Government Is Not Doing Enough
M T Osterholm
Clin Pharmacol Ther 82: 635-637; doi:10.1038/sj.clpt.6100421
Commentaries
The Importance of Including Swine and Poultry Workers in Influenza Vaccination Programs
G C Gray and W S Baker
Clin Pharmacol Ther 82: 638-641; doi:10.1038/sj.clpt.6100391
Use of Nanocarriers for Transdermal Vaccine Delivery
L B Lawson, L C Freytag and J D Clements
Clin Pharmacol Ther 82: 641-643; doi:10.1038/sj.clpt.6100425
State of the Art
State of the Art
Mass Spectrometry and Peptide-based Vaccine Development
I G Ovsyannikova, K L Johnson, H R Bergen III and G A Poland
Clin Pharmacol Ther 82: 644-652; advance online publication, October 31, 2007; doi:10.1038/sj.clpt.6100389
Heterogeneity in Vaccine Immune Response: The Role of Immunogenetics and the Emerging Field of Vaccinomics
G A Poland, I G Ovsyannikova, R M Jacobson and D I Smith
Clin Pharmacol Ther 82: 653-664; advance online publication, October 31, 2007; doi:10.1038/sj.clpt.6100415
Research
Articles
New Pre-pandemic Influenza Vaccines: An Egg- and Adjuvant-independent Human Adenoviral Vector Strategy Induces Long-lasting Protective Immune Responses in Mice
M A Hoelscher, L Jayashankar, S Garg, V Veguilla, X Lu, N Singh, J M Katz, S K Mittal and S Sambhara
Clin Pharmacol Ther 82: 665-671; advance online publication, October 24, 2007; doi:10.1038/sj.clpt.6100418
Heterologous Prime–Boost Strategy to Immunize Very Young Infants against Measles: Pre-clinical Studies in Rhesus Macaques
M F Pasetti, A Resendiz-Albor, K Ramirez, R Stout, M Papania, R J Adams, F P Polack, B J Ward, D Burt, S Chabot, J Ulmer, E M Barry and M M Levine
Clin Pharmacol Ther 82: 672-685; advance online publication, October 31, 2007; doi:10.1038/sj.clpt.6100420
HIV/AIDS Vaccines: 2007
H L Robinson
Clin Pharmacol Ther 82: 686-693; advance online publication, October 31, 2007; doi:10.1038/sj.clpt.6100408
White Blood Cell Telomerase Activity and Incident Respiratory Illness Among Community-Dwelling Elderly Vaccinated Against Seasonal Influenza
P V Targonski, C R Caldwell, M Strausbauch, P Wettstein, G A Poland and E G Tangalos
Clin Pharmacol Ther 82: 694-699; advance online publication, October 31, 2007; doi:10.1038/sj.clpt.6100410
Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide
R M Myers, S M Greiner, M E Harvey, G Griesmann, M J Kuffel, S A Buhrow, J M Reid, M Federspiel, M M Ames, D Dingli, K Schweikart, A Welch, A Dispenzieri, K-W Peng and S J Russell
Clin Pharmacol Ther 82: 700-710; advance online publication, October 31, 2007; doi:10.1038/sj.clpt.6100409
CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal Recipients
D R J Kuypers, H de Jonge, M Naesens, E Lerut, K Verbeke and Y Vanrenterghem
Clin Pharmacol Ther 82: 711-725; advance online publication, May 9, 2007; doi:10.1038/sj.clpt.6100216
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
M K Pasanen, H Fredrikson, P J Neuvonen and M Niemi
Clin Pharmacol Ther 82: 726-733; advance online publication, May 2, 2007; doi:10.1038/sj.clpt.6100220
Discovery & Development
Discovery
Cancer Mucosa Antigens as a Novel Immunotherapeutic Class of Tumor-associated Antigen
A E Snook, L C Eisenlohr, J L Rothstein and S A Waldman
Clin Pharmacol Ther 82: 734-739; advance online publication, September 26, 2007; doi:10.1038/sj.clpt.6100369
MF59 Is a Safe and Potent Vaccine Adjuvant for Flu Vaccines in Humans: What Did We Learn During Its Development?
D T O'Hagan, A Wack and A Podda
Clin Pharmacol Ther 82: 740-744; advance online publication, October 31, 2007; doi:10.1038/sj.clpt.6100402
Translational Medicine
Translational Research on Vaccines: Influenza as an Example
R B Belshe
Clin Pharmacol Ther 82: 745-749; advance online publication, October 31, 2007; doi:10.1038/sj.clpt.6100419
Development
Vaccine Immunopotentiators of the Future
V E J C Schijns and W G J Degen
Clin Pharmacol Ther 82: 750-755; advance online publication, October 3, 2007; doi:10.1038/sj.clpt.6100394
Regulation & Use
Practice
Vaccines and Autism: Evidence Does Not Support a Causal Association
F DeStefano
Clin Pharmacol Ther 82: 756-759; advance online publication, October 10, 2007; doi:10.1038/sj.clpt.6100407
Ethics
Lessons from the Failure of Human Papillomavirus Vaccine State Requirements
J L Schwartz, A L Caplan, R R Faden and J Sugarman
Clin Pharmacol Ther 82: 760-763; advance online publication, October 31, 2007; doi:10.1038/sj.clpt.6100397
